Skip to main content
SpringerLink
Log in

Oral, Transdermal, and Transurethral Therapies for Erectile Dysfunction

  • Chapter
Book cover Male Infertility and Sexual Dysfunction

Abstract

With the advent of the first Food and Drug Administration (FDA)-approved drug for the treatment of impotence, a formulation of alprostadil [synthetic prostaglandin E1 (PGE1)] for intracavernosal injection (Caverject, Pharmacia-Upjohn), the treatment of erectile dysfunction has entered a new era. Although injection therapy is considered the standard of pharmacologic therapies for the induction of erection, many men would prefer not to undertake this procedure. Other less invasive therapies, were they readily available, would be far more likely to be used both because of the lack of aversion to these treatments and the lack of pain, bruising, and fibrosis that have been associated with intracavernosal injection regardless of the drug employed.1

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Krane RJ. Impotence. J Urol 1995; 153:1841–1842

    PubMed  CAS  Google Scholar 

  2. NIH Consensus Conference. Impotence. JAMA 1993; 270: 83–90.

    Google Scholar 

  3. Yohimbine for male sexual dysfunction. Med Lett Drugs Ther 1994; 36: 115–116.

    Google Scholar 

  4. Masters WH, Johnson VE. Human Sexual Inadequacy. Boston: Little, Brown; 1970.

    Google Scholar 

  5. Carrier S, Brock G, Kour NW, Lue TF. Pathophysiology of erectile dysfunction. Urology 1993; 42: 468–481.

    PubMed  CAS  Google Scholar 

  6. Donatucci CF, Lue TF. Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res 1993; 5: 97–103.

    PubMed  CAS  Google Scholar 

  7. Spark RF, White RA, Connolly PB. Impotence is not always psychogenic: newer insights into hypothalamic-pituitary gonadal dysfunction. JAMA 1980; 243: 750–755.

    PubMed  CAS  Google Scholar 

  8. Kinsey AC, Pomeroy WB, Martine CE. Sexual Behavior in the Human Male. Philadelphia: W.B. Saunders; 1948.

    Google Scholar 

  9. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    PubMed  CAS  Google Scholar 

  10. Bennett AH. Preface. In: Bennett AH, ed. Impotence, Diagnosis and Management of Erectile Dysfunction. Philadelphia: W.B. Saunders; 1994.

    Google Scholar 

  11. Melman A, Tiefer L, Pedersen R. Evaluation of first 406 patients in urology department based Center for Male Sexual Dysfunction. Urology 1988; 32: 6–10.

    PubMed  CAS  Google Scholar 

  12. Gall H, Bahren W, Holzki G, et al. Results of multidisciplinary assessment of patients with erectile dysfunction. Hautarzt 1990; 41: 353–359.

    PubMed  CAS  Google Scholar 

  13. Schmidt CW Jr. Common male sexual disorders: impotence and premature ejaculation. In: Meyer JK, Schmidt CW Jr, Wise TN, eds. Clinical Management of Sexual Disorders. 2nd ed. Washington, DC: American Psychiatric Association; 1986: 173–187.

    Google Scholar 

  14. Carroll JL, Ellis DJ, Bagley DH. Age-related changes in hormones in impotent men. Jefferson Sexual Function Center. Urology 1990; 36: 42–46.

    PubMed  CAS  Google Scholar 

  15. Foreman MM, Doherty PC. Experimental approaches for the development of pharmacological therapies for erectile dysfunction. In: Riley AJ, Peet M, Wilson CA, eds. Sexual Pharmacology. New York: Oxford University Press; 1993: 87–113.

    Google Scholar 

  16. Ellis LR, Nellans RE, Kramer-Levien DJ, et al. Evaluation of the first 300 patients treated at an outpatient center for male sexual dysfunction. West J Med 1987; 147: 296–300.

    PubMed  CAS  Google Scholar 

  17. Porst H. The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence. Adv Prostaglandin Thromboxane Leukotriene Res 1995; 23: 539–544.

    CAS  Google Scholar 

  18. Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991; 145: 287–292.

    PubMed  CAS  Google Scholar 

  19. Morales A. Nonsurgical management options in impotence. Hosp Pract 1993; 28:15–16, 19–20, 23–24.

    Google Scholar 

  20. Morales A, Johnston B, Heaton JPW, et al. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115–1118.

    PubMed  CAS  Google Scholar 

  21. Montorsi F, Guazzoni G, Rigatti P, et al. Pharmacological management of erectile dysfunction. Drugs 1995; 50: 465–479.

    PubMed  CAS  Google Scholar 

  22. Foreman MM, Wernicke JF. Approaches for the development of oral drug therapies for erectile dysfunction. Semin Urol 1990; 8: 107–112.

    PubMed  CAS  Google Scholar 

  23. Afrodex and impotence. Med Lett Drugs Ther 1968; 10: 97–98.

    Google Scholar 

  24. Smith ER, Lee RL, Schnur SL, et al. Alpha,- adrenoceptor antagonists and male sexual behavior: I. Mating behavior. Physiol Behav 1987; 41: 7–14.

    PubMed  CAS  Google Scholar 

  25. Clark JT, Smith ER, Davidson JM. Enhancement of sexual motivation in male rats by yohimbine. Science 1984; 225: 847–849.

    PubMed  CAS  Google Scholar 

  26. Smith ER, Lee RL, Schnur SL, et al. Alpha,- adrenoceptor antagonists and male sexual behavior: II. Erectile and ejaculatory reflexes. Physiol Behav 1987; 41: 15–19.

    PubMed  CAS  Google Scholar 

  27. Morales A, Surridge DH, Marshall PG. Yohimbine for treatment of impotence in diabetes. N Engl J Med 1981; 305: 1221.

    PubMed  CAS  Google Scholar 

  28. Buffum J. Pharmacosexology update: yohimbine and sexual function. J Psychoactive Drugs 1985; 17: 131–132.

    PubMed  CAS  Google Scholar 

  29. Reid K, Surridge DH, Morales A, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 1987; 2: 421–423.

    PubMed  CAS  Google Scholar 

  30. Riley AJ. Yohimbine in the treatment of erectile disorder. Br J Clin Pract 1994; 48: 133–136.

    PubMed  CAS  Google Scholar 

  31. Morales A, Condra M, Owen JA, et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol 1987; 137: 1168–1172.

    PubMed  CAS  Google Scholar 

  32. Sonda LP, Mazo R, Chancellor MB. The role of yohimbine for the treatment of erectile impotence. J Sex Marital Ther 1990; 16: 15–21.

    PubMed  CAS  Google Scholar 

  33. Riley AJ. Double blind placebo trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual Marital Ther 1996; 4: 17–26.

    Google Scholar 

  34. Susset JG, Tessier CD, Wincze J, et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol 1989; 141: 1360–1363.

    PubMed  CAS  Google Scholar 

  35. Charney DS, Heninger GR. Alpha 2adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. Arch Gen Psychiatry 1986; 43: 1037–1041.

    PubMed  CAS  Google Scholar 

  36. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazodone on psychogenic impotence: a randomized, double-blind, placebo-controlled study. Urology 1994; 44: 732–736.

    PubMed  CAS  Google Scholar 

  37. Danjou P, Alexandre L, Warot D, et al. Assessment of erectogenic properties of apomorphine and yohimbine in man. Br J Clin Pharmacol 1988; 26: 733–739.

    PubMed  CAS  Google Scholar 

  38. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992; 53: 207–209.

    PubMed  CAS  Google Scholar 

  39. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–122.

    PubMed  CAS  Google Scholar 

  40. Brown CM, MacKinnon AC, Redfern WS, et al. The pharmacology of RS-15385–197, a potent and selective α2-adrenoceptor antagonist. Br J Pharmacol 1993; 108: 516–525.

    PubMed  CAS  Google Scholar 

  41. Munoz M, Bancroft J, Turner M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 1. The erectile response to erotic stimuli in volunteers. Psychopharmacology (Berl) 1994; 115: 463–470.

    CAS  Google Scholar 

  42. Bancroft J, Munoz M, Beard M, et al. The effects of a new alpha-2 adrenoceptor antagonist on sleep and nocturnal penile tumescence in normal male volunteers and men with erectile dysfunction. Psychosom Med 1995; 57: 345–356.

    PubMed  CAS  Google Scholar 

  43. Munoz M, Bancroft J, Beard M. Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers. Psychopharmacology (Berl) 1994; 115: 471–477.

    CAS  Google Scholar 

  44. Riley AJ. Alpha adrenoceptors and human sexual function. In: Bancroft J ed. The Pharmacology of Sexual Function and Dysfunction. New York: Excerpta Medica; 1995: 307–322.

    Google Scholar 

  45. Linnankoski I, Gronroos M, Carlson S, et al. Increased sexual behavior in male Macaca arctoides monkeys produced by atipamezole, a selective alpha 2-adrenoceptor antagonist. Pharmacol Biochem Behav 1992; 42: 197–200.

    PubMed  CAS  Google Scholar 

  46. Grossman E, Rosenthal T, Peleg E, et al. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol 1993; 22: 22–26.

    PubMed  CAS  Google Scholar 

  47. Kirkeby HJ, Forman A, Sorensen S, et al. Alpha-adrenoceptor function in isolated penile circumflex veins from potent and impotent men. J Urol 1989; 142: 1369–1371.

    PubMed  CAS  Google Scholar 

  48. Steers WD, McConnell J, Benson GS. Some pharmacologic effects of yohimbine on human and rabbit penis. J Urol 1984; 131: 799–802.

    PubMed  CAS  Google Scholar 

  49. Haslam M. A trial of idazoxan and yohimbine in erectile dysfunction. J Sex Marital Ther 1996; 7: 261–266.

    Google Scholar 

  50. Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 1986; 87: 495–500.

    PubMed  CAS  Google Scholar 

  51. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988; 109: 162–163.

    PubMed  CAS  Google Scholar 

  52. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 39–41.

    PubMed  CAS  Google Scholar 

  53. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994; 6: 37–41.

    PubMed  CAS  Google Scholar 

  54. Wagner G, Lacy S, Lewis R, et al. Buccal phentolamine. A pilot trial for male erectile dysfunction at three separate clinics. Int J Impot Res 1994; 6: D78.

    Google Scholar 

  55. Nordling J, Meyhoff HH, Hald T. Sympatholytic effect on striated urethral sphincter. A peripheral or central nervous system effect? Scand J Urol Nephrol 1981; 15: 173–180.

    PubMed  CAS  Google Scholar 

  56. Blum MD, Bahnson RR, Porter TN, et al. Effect of local alpha-adrenergic blockade on human penile erection. J Urol 1985; 134: 479–481.

    PubMed  CAS  Google Scholar 

  57. Mirin SM, Meyer RE, Mendelson JH, et al. Opiate use and sexual function. Am J Psychiatry 1980; 137: 909–915.

    PubMed  CAS  Google Scholar 

  58. Smith DE, Moser C, Wesson DR, et al. A clinical guide to the diagnosis and treatment of heroin-related sexual dysfunction. J Psychoactive Drugs 1982; 14: 91–99.

    PubMed  CAS  Google Scholar 

  59. Braude MC, Morrison JM. Preclinical toxicity studies of naltrexone. NIDA Res Monogr 1976; 9: 16–26.

    PubMed  Google Scholar 

  60. Mendelson JH, Ellingboe J, Keuhnle JC, et al. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1978; 3: 231–236.

    PubMed  CAS  Google Scholar 

  61. Berendsen HH, Gower AJ. Opiate-androgen interactions in drug-induced yawning and penile erections in the rat. Neuroendocrinology 1986; 42: 185–190.

    PubMed  CAS  Google Scholar 

  62. Ferrari F, Baggio G. Potentiation of the aphrodisiac effect of N-n-propyl-norapomorphine by naloxone. Eur J Pharmacol 1982; 81: 321–326.

    PubMed  CAS  Google Scholar 

  63. Goldstein JA. Erectile function and naltrexone. Ann Intern Med 1996; 105: 799–801.

    Google Scholar 

  64. Fabbri A, Jannini EA, Gnessi L, et al. Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology 1989; 14: 103–111.

    PubMed  CAS  Google Scholar 

  65. Billington CJ, Shafer RB, Morley JE. Effects of opioid blockade with nalmefene in older impotent men. Life Sci 1990; 47: 799–805.

    PubMed  CAS  Google Scholar 

  66. Brennemann W, Stitz B, Van Ahlen H, et al. Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone-a double-blind study. J Androl 1993; 14: 407410.

    Google Scholar 

  67. Barbeau A. L-dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med Assoc J 1969; 101: 59–68.

    PubMed  CAS  Google Scholar 

  68. Gower AJ, Berendsen HG, Princen MM, et al. The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol 1984; 103: 81–89.

    PubMed  CAS  Google Scholar 

  69. Pomerantz SM. Apomorphine facilitates male sexual behavior of rhesus monkeys. Pharmacol Biochem Behav 1990; 35: 659–664.

    PubMed  CAS  Google Scholar 

  70. Lal S, Tesfaye Y, Thavundayil JX, et al. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 329–339.

    PubMed  CAS  Google Scholar 

  71. Segraves RT, Bari M, Segraves K, et al. Effect of apomorphine on penile tumescence in men with psychogenic impotence. J Urol 1991; 145: 1174–1175.

    PubMed  CAS  Google Scholar 

  72. Doherty PC, Wilser PA. Effects of opiate antagonists on quinpirole-induced penile erection and yawning in the male rat. Soc Neurosci Abstr 1992; 18: 659.

    Google Scholar 

  73. Heaton JP, Varrin SJ, Morales A. The characterization of a bio-assay of erectile function in a rat model. J Urol 1991; 145: 1099–1102.

    PubMed  CAS  Google Scholar 

  74. Lal S, De la Vega CE. Apomorphine and psychopathology. J Neurol Neurosurg Psychiatry 1975; 38: 722–726.

    PubMed  CAS  Google Scholar 

  75. Lal S, Ackman D, Thavundayil JX, et al. Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984: 8: 695–699.

    PubMed  CAS  Google Scholar 

  76. Lal S, Laryea E, Thavundayil JX, et al. Apomorphine-induced penile tumescence in impotent patients-preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11: 235–242.

    PubMed  CAS  Google Scholar 

  77. Murphy M. The pharmacology of erection and erectile dysfunction. In: Gregoire A, Pryor JP eds. Impotence: An Integrated Approach to Clinical Practice. New York: Churchill Livingstone; 1996: 55–77.

    Google Scholar 

  78. Carter JN, Tyson JE, Tolis G, et al. Prolactinsecreting tumors and hypogonadism in 22 men. N Engl J Med 1978; 299: 847–852.

    PubMed  CAS  Google Scholar 

  79. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res 1985; 22: 196–203.

    PubMed  CAS  Google Scholar 

  80. Franks S, Jacobs HS. Hyperprolactinaemia. Clin Endocrinol Metab 1983; 12: 641–668.

    PubMed  CAS  Google Scholar 

  81. Ahlenius S, Engel J, Larsson K, et al. Effects of pergolide and bromocriptine on male rat sexual behavior. J Neural Trans 1982; 54: 165–170.

    CAS  Google Scholar 

  82. Doherty PC, Bartke A, Smith MS. Differential effects of bromocriptine treatment on LH release and copulatory behavior in hyperprolactinemic male rats. Horm Behav 1981; 15: 436–450.

    PubMed  CAS  Google Scholar 

  83. Lal S, Kiely ME, Thavundayil JX, et al. Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study. J Psychiatry Neurosci 1991; 16: 262–266.

    PubMed  CAS  Google Scholar 

  84. Ambrosi B, Bara R, Travaglini P, et al. Study of the effects of bromocriptine on sexual impotence. Clin Endocrinol (Oxf) 1977; 7: 417–421.

    CAS  Google Scholar 

  85. Pierini AA, Nusimovich B. Male diabetic sexual impotence: effects of dopaminergic agents. Arch Androl 1981; 6: 347–350.

    PubMed  CAS  Google Scholar 

  86. Foreman MM, Hall JL. Effects of DZ dopaminergic receptor stimulation on male rats sexual behavior. J Neural Trans 1987; 68: 153–170.

    CAS  Google Scholar 

  87. Doherty PC, Wisler PA. Stimulatory effects of quinelorane on yawning and penile erection in the rat. Life Sci 1994; 54: 507–514.

    PubMed  CAS  Google Scholar 

  88. Pomerantz SM. Quinelorane (LY163502), a D2 dopamine receptor agonist, acts centrally to facilitate penile erections of male rhesus monkeys. Pharmacol Biochem Behav 1991; 39: 123–128.

    PubMed  CAS  Google Scholar 

  89. Foreman MM. Disorders of sexual response: pioneering new pharmaceutical and therapeutic opportunities. Exp Opin Invest Drugs 1995; 4: 621–636.

    CAS  Google Scholar 

  90. Heaton JP, Morales A, Adams MA. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200–206.

    PubMed  CAS  Google Scholar 

  91. Murray MJ, Hooberman D. Fluoxetine and prolonged erection. Am J Psychiatry 1993; 150: 167–168.

    PubMed  CAS  Google Scholar 

  92. Seftel AD, Saenz de Tejada I, Szetela B, et al. Clozapine-associated priapism: a case report. J Urol 1992; 147: 146–148.

    PubMed  CAS  Google Scholar 

  93. Dawson-Butterworth K. Priapism and phenothiazines Br Med J 1970; 4: 118.

    PubMed  CAS  Google Scholar 

  94. Raskin DE. Trazodone and priapism. Am J Psychiatry 1985; 142: 142–143.

    PubMed  CAS  Google Scholar 

  95. Szele FG, Murphy DL, Garrick NA. Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in non-human primates. Life Sci 1988; 43: 1297–1303.

    PubMed  CAS  Google Scholar 

  96. Berendsen HH, Jenck F, Broekkamp CL. Involvement of 5-HT1C-receptors in drug-induced penile erections in rats. Psychopharmacology (Berl) 1990; 101: 57–61.

    CAS  Google Scholar 

  97. Steers WD, de Groat WC. Effects of mchlorophenylpiperazine on penile and bladder function in rats. Am J Physiol 1989; 257: R1441–1449.

    PubMed  CAS  Google Scholar 

  98. Adaikan PG, Ng SC, Chan C, et al. Oral trazodone in the treatment of total secondary impotence in a diabetic patient. Br J Urol 1991; 68: 212–213.

    PubMed  CAS  Google Scholar 

  99. Lance R, Albo M, Costabile RA, et al. Oral trazodone as empirical therapy for erectile dysfunction: a retrospective review. Urology 1995; 46: 117–120.

    PubMed  CAS  Google Scholar 

  100. Bondil P. The combination of oral trazodonemoxisylyte: diagnostic and therapeutic value in impotence. Report of 110 cases. Prog Urol 1992; 2: 671–674.

    PubMed  CAS  Google Scholar 

  101. Kurt U, Ozkardes H, Altug U, et al. The efficacy of antiserotoninergic agents in the treatment of erectile dysfunction. J Urol 1994; 152: 407–409.

    PubMed  CAS  Google Scholar 

  102. Abber JC, Lue TF, Luo JA, et al. Priapism induced by chlorpromazine and trazodone: mechanism of action. J Urol 1987; 137: 1039–1042.

    PubMed  CAS  Google Scholar 

  103. Saenz de Tejada I, Ware JC, Blanco R et al. Pathophysiology of prolonged penile erection associated with trazodone use. J Urol 1991; 145: 60–64.

    PubMed  CAS  Google Scholar 

  104. Ware JC, Rose FV, McBrayer RH. The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 1994; 17: 544–550.

    PubMed  CAS  Google Scholar 

  105. Azadzoi KM, Payton T, Krane RJ, et al. Effects of intracavernosal trazodone hydrochloride: animal and human studies. J Urol 1990; 144: 1277–1282.

    PubMed  CAS  Google Scholar 

  106. Horby-Petersen J, Nielsen FC, Schmidt PF. Penile tumescence after injection of a serotonin antagonist (ketanserin). BrJ Urol 1988; 62: 277–278.

    CAS  Google Scholar 

  107. Power-Smith P. Beneficial sexual side-effects from fluoxetine. Br J Psychiatry 1994; 164: 249–250.

    PubMed  CAS  Google Scholar 

  108. Smith DM, Levitte SS. Association of fluoxetine and return of sexual potency in three elderly men. J Clin Psychiatry 1993; 54: 317–319.

    PubMed  CAS  Google Scholar 

  109. Sparwasser C, Drescher P, Will JA, et al. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms. J Urol 1994; 152: 2159–2163.

    PubMed  CAS  Google Scholar 

  110. Trigo-Rocha F, Hsu GL, Donatucci CF, et al. Intracellular mechanism of penile erection in monkeys. Neurourol Urodyn 1994; 13: 71–80.

    PubMed  CAS  Google Scholar 

  111. Stief CG, Uckert S, Truss MC, et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in human cavernous smooth muscle: characterization and functional effects of PDEinhibitors in vitro and in vivo. Int J Impotence Res 1995; 7: 6.

    Google Scholar 

  112. Knispel HH, Gerhardus T, Beckmann R, et al. Relaxant effects of phosphodiesterase (PDE) inhibitors on rabbit corpus cavernosum smooth muscle. Int J Impotence Res 1995; 7: 13.

    Google Scholar 

  113. Boolell M, Gepi-Attee S, Gingell C, et al. UK-92,480, a new oral treatment for erectile dysfunction. A double-blind, placebo controlled crossover study demonstrating dose response with Rigiscan and efficacy with outpatient diary. J Urol 1996; 155: 495A.

    Google Scholar 

  114. Korenman SG, Viosca SP. Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Am Geriatr Soc 1993; 41: 363–366.

    PubMed  CAS  Google Scholar 

  115. Allenby KS, Burris JF, Mroczek WJ. Pentoxifylline in the treatment of vascular impotence-case reports. Angiology 1991; 42: 418–420.

    PubMed  CAS  Google Scholar 

  116. Althof SE, Turner LA, Levine SB, et al. Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long-term prospective study. J Sex Marital Ther 1991; 17: 101–112.

    PubMed  CAS  Google Scholar 

  117. Turner LA, Althof SE, Levine SB, et al. Twelve-month comparison of two treatments for erectile dysfunction: self-injection versus external vacuum devices. Urology 1992; 39: 139–144.

    PubMed  CAS  Google Scholar 

  118. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin E, for impotency. Urology 1994; 43: 84–87.

    PubMed  CAS  Google Scholar 

  119. Owen JA, Saunders F, Harris C, et al. Topical nitroglycerin: a potential treatment for impotence. J Urol 1989; 141: 546–548.

    PubMed  CAS  Google Scholar 

  120. Heaton JP, Morales A, Owen J, et al. Topical glyceryltrinitrate causes measurable penile arterial dilation in impotent men. J Urol 1990; 143: 729–731.

    PubMed  CAS  Google Scholar 

  121. Talley JD, Crawley IS. Transdermal nitrate, penile erection, and spousal headache. Ann Intern Med 1985; 103: 804.

    PubMed  CAS  Google Scholar 

  122. Nunez BD, Anderson DC Jr. Nitroglycerin ointment in the treatment of impotence. J Urol 1993; 150: 1241–1243.

    PubMed  CAS  Google Scholar 

  123. Sonksen J, Biering-Sorensen F. Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured. Paraplegia 1992; 30: 554–557.

    PubMed  CAS  Google Scholar 

  124. Claes H, Baert L. Transcutaneous nitroglycerin therapy in the treatment of impotence. Urol Int 1989; 44: 309–312.

    PubMed  CAS  Google Scholar 

  125. Meyhoff HH, Rosenkilde P, Bodker A. Noninvasive management of impotence with trans-cutaneous nitroglycerin. Br J Urol 1992; 69: 88–90.

    PubMed  CAS  Google Scholar 

  126. Chancellor MB, Rivas DA, Panzer DE, et al. Prospective comparison of topical minoxidil to vaccum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal cord injury. Urology 1994; 43: 365–369.

    PubMed  CAS  Google Scholar 

  127. Radomski SB, Herschorn S, Rangaswamy S. Topical minoxidil in the treatment of male erectile dysfunction. J Urol 1994; 151: 1225–1226.

    PubMed  CAS  Google Scholar 

  128. Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991; 146: 50–53.

    PubMed  CAS  Google Scholar 

  129. Kim ED, el-Rashidy R, McVary KT. Papaverine topical gel for treatment of erectile dysfunction. J Urol 1995; 153: 361–365.

    PubMed  CAS  Google Scholar 

  130. Kim ED, McVary KT. Topical prostaglandin-E, for the treatment of erectile dysfunction. J Urol 1995; 153: 1828–1830.

    PubMed  CAS  Google Scholar 

  131. Wolfson B, Pickett S, Scott NE, et al. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993; 42: 73–75.

    PubMed  CAS  Google Scholar 

  132. Padma-Nathan H, Bennett A, Gesundheit N, et al. Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE). J Urol 1995; 153: 472A.

    Google Scholar 

  133. Padma-Nathan H, Auerbach SM, Barada JH, et al. Multicenter double-blind, placebo-controlled trial of transurethral alprostadil in men with chronic erectile dysfunciton. J Urol 1996; 155: 496A.

    Google Scholar 

  134. Padma-Nathan H, Keller T, Poppiti R, et al. Hemodynamic effects of intraurethral alprostadil: The Medicated Urethral System for Erection (MUSE). J Urol 1994; 151: 345A.

    Google Scholar 

  135. Lazzeri M, Barbanti G, Beneforti P, et al. Intraurethrally infused capsaicin induces penile erection in humans. Scand J Urol Nephrol 1994; 28: 409–412.

    PubMed  CAS  Google Scholar 

  136. Lue TF. Physiology of erection and pathophysiology of impotence. In: Walsh PC, Retik AB, Stamey TA, Vaughan JED, eds. Campbell’s Urology. Philadelphia: W.B. Saunders; 1992: 709–728.

    Google Scholar 

  137. Fuchs AM, Mehringer CM, Rajfer J. Anatomy of penile venous drainage in potent and impotent men during cavernosography. J Urol 1989; 141: 1353–1356.

    PubMed  CAS  Google Scholar 

  138. Vardi Y. Corporal response to intra-spongiosal injection of vasoactive drugs. Int J Impotence Res 1995; 7: 8.

    Google Scholar 

Download references

Authors
  1. Paul C. Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Andrology and Male Infertility Department of Urology, Tulane University School of Medicine, 1430 Tulane Avenue SL 42, 70112-2699, New Orleans, LA, USA

    Wayne J. G. Hellstrom (Associate Professor Urology, Chief) (Associate Professor Urology, Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Doherty, P.C. (1997). Oral, Transdermal, and Transurethral Therapies for Erectile Dysfunction. In: Hellstrom, W.J.G. (eds) Male Infertility and Sexual Dysfunction. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1848-7_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1848-7_33

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7310-3

  • Online ISBN: 978-1-4612-1848-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation